Citations (74)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Belén Atienza-Mateo, Diana Prieto-Peña, Esther F. Vicente-Rabaneda, Ricardo Blanco, Miguel A. González-Gay & Santos Castañeda. (2022) Utility of tocilizumab in autoimmune eye diseases. Expert Opinion on Biological Therapy 22:6, pages 789-799.
Read now
Read now
Caiyun You, Andres F. Lasave, Buraa Kubaisi, Sarah Syeda, Lina Ma, Kelvin Cheng Kah Wai, Mikhail Hernandez Diaz, Marisa Walsh, Andrew Stephenson, Alyssa Montieth & C. Stephen Foster. (2020) Long-term outcomes of systemic corticosteroid-sparing immunomodulatory therapy for Birdshot Retinochoroidopathy. Ocular Immunology and Inflammation 28:6, pages 966-974.
Read now
Read now
Alfredo Adán, Aina Moll-Udina, Carmen Alba-Linero, Juan Pablo Figueroa-Vercellino & Victor Llorenç. (2019) Recent progress in the treatment of uveitic macular edema. Expert Review of Ophthalmology 14:4-5, pages 227-236.
Read now
Read now
Emmett T. Cunningham, Ralph D. Levinson, Alastair K. Denniston, Antoine P. Brézin & Manfred Zierhut. (2017) Birdshot Chorioretinopathy. Ocular Immunology and Inflammation 25:5, pages 589-593.
Read now
Read now
Vanesa Calvo-Río, Ricardo Blanco, Montserrat Santos-Gómez, David Díaz-Valle, Esperanza Pato, Javier Loricera, María C. González-Vela, Rosalía Demetrio-Pablo, José L. Hernández & Miguel A. González-Gay. (2017) Efficacy of Anti-IL6-Receptor Tocilizumab in Refractory Cystoid Macular Edema of Birdshot Retinochoroidopathy Report of Two Cases and Literature Review. Ocular Immunology and Inflammation 25:5, pages 609-614.
Read now
Read now
Christoph M. E. Deuter, Manfred Zierhut, Annette Igney-Oertel, Theodoros Xenitidis, Alexandra Feidt, Bianka Sobolewska, Nicole Stuebiger & Deshka Doycheva. (2017) Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatment. Ocular Immunology and Inflammation 25:2, pages 215-220.
Read now
Read now
Julie Gueudry, Jennifer E. Thorne, Rakesh Bansie, Juergen Braun, P. Martin van Hagen & Bahram Bodaghi. (2017) Biologic Therapy for HLA-B27-associated Ocular Disorders. Ocular Immunology and Inflammation 25:2, pages 169-178.
Read now
Read now
Valeria Kheir, Jean Vaudaux & Yan Guex-Crosier. (2016) Review of the latest systemic treatments for chronic non-infectious uveitis. Expert Review of Ophthalmology 11:2, pages 111-133.
Read now
Read now
Victor Menezo & Simon RJ Taylor. (2014) Birdshot uveitis: current and emerging treatment options. Clinical Ophthalmology 8, pages 73-81.
Read now
Read now
Robert J Barry, Quan Dong Nguyen, Richard W Lee, Philip I Murray & Alastair K Denniston. (2014) Pharmacotherapy for uveitis: current management and emerging therapy. Clinical Ophthalmology 8, pages 1891-1911.
Read now
Read now
Kyungmin Lee, Asima Bajwa, Clovis A Freitas-Neto, Jamie Lynne Metzinger, Bailey A Wentworth & C Stephen Foster. (2014) A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II. Expert Opinion on Biological Therapy 14:11, pages 1651-1666.
Read now
Read now
Basilio Colligris, Almudena Crooke, Fernando Huete-Toral & Jesus Pintor. (2014) An update on dry eye disease molecular treatment: advances in drug pipelines. Expert Opinion on Pharmacotherapy 15:10, pages 1371-1390.
Read now
Read now
Emmett T. Cunningham$suffix/text()$suffix/text() & Manfred Zierhut. (2014) The Promise and Limitations of TNF-α Inhibition for Uveitis. Ocular Immunology and Inflammation 22:2, pages 87-89.
Read now
Read now
Alfredo Adán, Marina Mesquida & Victor Llorenç. (2013) Biologic drugs in noninfectious uveitis: an update. Expert Review of Ophthalmology 8:5, pages 501-516.
Read now
Read now
Robert M Beardsley, Eric B Suhler, James T Rosenbaum & Phoebe Lin. (2013) Pharmacotherapy of scleritis: current paradigms and future directions. Expert Opinion on Pharmacotherapy 14:4, pages 411-424.
Read now
Read now
Anna Dastiridou, Christos Kalogeropoulos, Periklis Brazitikos, Chrysanthos Symeonidis & Sofia Androudi. (2012) New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment
. Expert Review of Clinical Pharmacology 5:5, pages 543-555.
Read now
Read now
Articles from other publishers (58)
Irmak Karaca, Gunay Uludag, Wataru Matsumiya, Jonathan Regenold, Christopher Or, Azadeh Mobasserian, Muhammad Sohail Halim, Moosa Zaidi, Sherin Lajevardi, Ami Dongchau, Hashem Ghoraba & Quan Dong Nguyen. (2022) Six-month outcomes of infliximab and tocilizumab therapy in non-infectious retinal vasculitis. Eye 37:11, pages 2197-2203.
Crossref
Crossref
Summaiyya Waseem, Syed Hassan Ahmed, Sharmeen Fatima, Taha Gul Shaikh & Jawad Ahmed. (2022) SARS-CoV-2 vaccination and uveitis: Are they linked?. Annals of Medicine and Surgery 81, pages 104472.
Crossref
Crossref
Zulvikar Syambani Ulhaq, Gita Vita Soraya, Budu & Lely Retno Wulandari. (2020) The role of IL-6-174 G/C polymorphism and intraocular IL-6 levels in the pathogenesis of ocular diseases: a systematic review and meta-analysis. Scientific Reports 10:1.
Crossref
Crossref
Wanhai Ke, Li Zhang & Yan Dai. (2020) The role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs). Thoracic Cancer 11:4, pages 835-839.
Crossref
Crossref
Jinjing Liu, Dong Yan, Zhimian Wang, Yunjiao Yang, Shangzhu Zhang, Di Wu, Lingyi Peng, Zhichun Liu & Wenjie Zheng. (2020) Tocilizumab in the treatment of severe and refractory parenchymal neuro-Behçet’s syndrome: case series and literature review. Therapeutic Advances in Musculoskeletal Disease 12, pages 1759720X2097190.
Crossref
Crossref
Samendra Karkhur, Murat Hasanreisoglu, Erin Vigil, Muhammad Sohail Halim, Muhammad Hassan, Carlos Plaza, Nam V. Nguyen, Rubbia Afridi, Anh T. Tran, Diana V. Do, Yasir J. Sepah & Quan Dong Nguyen. (2019) Interleukin-6 inhibition in the management of non-infectious uveitis and beyond. Journal of Ophthalmic Inflammation and Infection 9:1.
Crossref
Crossref
Amruta Trivedi & Constance Katelaris. (2019) The use of biologic agents in the management of uveitis. Internal Medicine Journal 49:11, pages 1352-1363.
Crossref
Crossref
Nuria Vegas-Revenga, Vanesa Calvo-Río, Marina Mesquida, Alfredo Adán, María Victoria Hernández, Emma Beltrán, Elia Valls Pascual, David Díaz-Valle, Gisela Díaz-Cordovés, Marisa Hernandez-Garfella, Lucía Martínez-Costa, Inmaculada Calvo, Antonio Atanes, Luis F. Linares, Consuelo Modesto, Carmen González-Vela, Rosalia Demetrio-Pablo, Elena Aurrecoechea, Miguel Cordero, Lucía C. Domínguez-Casas, Belén Atienza-Mateo, José Luis Martín-Varillas, Javier Loricera, Natalia Palmou-Fontana, José L. Hernández, Miguel A. González-Gay & Ricardo Blanco. (2019) Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients. American Journal of Ophthalmology 200, pages 85-94.
Crossref
Crossref
Filipe Martins, Gerasimos P Sykiotis, Michel Maillard, Montserrat Fraga, Camillo Ribi, Thierry Kuntzer, Olivier Michielin, Solange Peters, Georges Coukos, Francois Spertini, John A Thompson & Michel Obeid. (2019) New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. The Lancet Oncology 20:1, pages e54-e64.
Crossref
Crossref
Marina Mesquida, Victor Llorenç & Alfredo Adán. 2019. Treatment of Non-infectious Uveitis. Treatment of Non-infectious Uveitis
95
112
.
Athimalaipet V. Ramanan, Andrew D. Dick, Ashley P. Jones, Catherine Guly, Ben Hardwick, Helen Hickey, Richard Lee, Andrew McKay & Michael W. Beresford. (2018) A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial). BMC Rheumatology 2:1.
Crossref
Crossref
J. Ruiz-Medrano, D. Díaz-Valle, R. Cuiña, J.A. Gegúndez, J. Chhablani, P.D. Majumder & R. Gutierrez-Bonet. (2018) The role of tocilizumab in the treatment of inflammatory diseases of the eye and orbit: A useful alternative. Journal Français d'Ophtalmologie 41:8, pages 759-766.
Crossref
Crossref
Yanxia Ding, Chaoran Li, Jinjing Liu, Xin Yu, Yining Wang, Jing Shi, Lu Li, Jiaxin Zhou, Li Wang, Hua Chen, Yan Zhao & Wenjie Zheng. (2018) Tocilizumab in the treatment of severe and/or refractory vasculo-Behçet’s disease: a single-centre experience in China. Rheumatology.
Crossref
Crossref
Marina MesquidaBlanca MolinsVictor LlorençMaría V. Hernández, Gerard EspinosaMaite Sainz de la MazaAlfredo Adán. (2018) TWENTY-FOUR MONTH FOLLOW-UP OF TOCILIZUMAB THERAPY FOR REFRACTORY UVEITIS-RELATED MACULAR EDEMA. Retina 38:7, pages 1361-1370.
Crossref
Crossref
Avni P. Finn, Robert T. Keenan & Glenn J. Jaffe. (2018) RECONSTITUTION OF THE ELLIPSOID ZONE WITH TOCILIZUMAB IN AUTOIMMUNE RETINOPATHY. RETINAL Cases & Brief Reports Publish Ahead of Print.
Crossref
Crossref
Mathilde Leclercq, M. Le Besnerais, V. Langlois, N. Girszyn, Y. Benhamou, C. Ngo, H. Levesque, M. Muraine & J. Gueudry. (2018) Tocilizumab for the treatment of birdshot uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy: two cases report and literature review. Clinical Rheumatology 37:3, pages 849-853.
Crossref
Crossref
C. Nathaniel Roybal, Gabriel Velez, Marcus A. Toral, Stephen H. Tsang, Alexander G. Bassuk & Vinit B. Mahajan. (2018) Personalized Proteomics in Proliferative Vitreoretinopathy Implicate Hematopoietic Cell Recruitment and mTOR as a Therapeutic Target. American Journal of Ophthalmology 186, pages 152-163.
Crossref
Crossref
Marina Mesquida, Blanca Molins, Víctor Llorenç, Maite Sáinz de la Maza & Alfredo Adán. (2017) Targeting interleukin-6 in autoimmune uveitis. Autoimmunity Reviews 16:10, pages 1079-1089.
Crossref
Crossref
Forouhe Zahir-Jouzdani, Fatemeh Atyabi & Nazanin Mojtabavi. (2017) Interleukin-6 participation in pathology of ocular diseases. Pathophysiology 24:3, pages 123-131.
Crossref
Crossref
Giuseppe Lopalco, Claudia Fabiani, Jurgen Sota, Orso Maria Lucherini, Gian Marco Tosi, Bruno Frediani, Florenzo Iannone, Mauro Galeazzi, Rossella Franceschini, Donato Rigante & Luca Cantarini. (2017) IL-6 blockade in the management of non-infectious uveitis. Clinical Rheumatology 36:7, pages 1459-1469.
Crossref
Crossref
Toshio Tanaka & Masashi Narazaki. (2017) Interleukin-6 Inhibition in Inflammatory Diseases: Results Achieved and Tasks to Accomplish. Journal of Scleroderma and Related Disorders 2:2_suppl, pages S20-S28.
Crossref
Crossref
F. Alokaily, A. Al Saati & A. Jawad. (2017) Successful treatment of Behçet’s uveitis with Tocilizumab. Saudi Journal of Ophthalmology 31:1, pages 42-44.
Crossref
Crossref
Christoph Tappeiner, Marina Mesquida, Alfredo Adán, Jordi Anton, Athimalaipet V. Ramanan, Ester Carreno, Friederike Mackensen, Kaisu Kotaniemi, Joke H. de Boer, Rosa Bou, Carmen García de Vicuña & Arnd Heiligenhaus. (2016) Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. The Journal of Rheumatology 43:12, pages 2183-2188.
Crossref
Crossref
Nicholas J. D. Gower, Robert J. Barry, Matthew R. Edmunds, Lucy C. Titcomb & Alastair K. Denniston. (2016) Drug discovery in ophthalmology: past success, present challenges, and future opportunities. BMC Ophthalmology 16:1.
Crossref
Crossref
C Fardeau, E Champion, N Massamba & P LeHoang. (2016) Uveitic macular edema. Eye 30:10, pages 1277-1292.
Crossref
Crossref
Sergio Schwartzman. (2016) Advancements in the management of uveitis. Best Practice & Research Clinical Rheumatology 30:2, pages 304-315.
Crossref
Crossref
Sepideh Faez, Ann-Marie Lobo, Sebastian H. Unizony, John H. Stone, George N. Papaliodis & Lucia Sobrin. (2014) Ocular inflammatory disease in patients with polymyalgia rheumatica: A case series and review of the literature. Clinical Rheumatology 35:1, pages 251-258.
Crossref
Crossref
Jared E. Knickelbein, Karen R. Armbrust, Meredith Kim, H. Nida Sen & Robert B. Nussenblatt. 2017. Pharmacologic Therapy of Ocular Disease. Pharmacologic Therapy of Ocular Disease
231
268
.
Sergio Schwartzman & Monica Schwartzman. (2014) The Use of Biologic Therapies in Uveitis. Clinical Reviews in Allergy & Immunology 49:3, pages 307-316.
Crossref
Crossref
Miguel Cordero-Coma & Lucia Sobrin. (2015) Anti–tumor necrosis factor-α therapy in uveitis. Survey of Ophthalmology 60:6, pages 575-589.
Crossref
Crossref
Chiharu Iwahashi, Minoru Fujimoto, Shintaro Nomura, Satoshi Serada, Kei Nakai, Nobuyuki Ohguro, Kohji Nishida & Tetsuji Naka. (2015) CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6. Experimental Eye Research 140, pages 53-64.
Crossref
Crossref
Gabriele Simonini, Rolando Cimaz, Gareth T. Jones & Gary J. Macfarlane. (2015) Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: The current evidence from a systematic review. Seminars in Arthritis and Rheumatism 45:2, pages 238-250.
Crossref
Crossref
Muhammad A. Khan, Muhammad Haroon & James T. Rosenbaum. (2015) Acute Anterior Uveitis and Spondyloarthritis: More Than Meets the Eye. Current Rheumatology Reports 17:9.
Crossref
Crossref
Melissa A. Lerman & C. Egla Rabinovich. (2015) The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis. Pediatric Drugs 17:4, pages 283-301.
Crossref
Crossref
E. Feurer, P. Bielefeld, D. Saadoun & P. Sève. (2015) Uvéites et biothérapies. La Revue de Médecine Interne 36:2, pages 107-116.
Crossref
Crossref
Laura J. Kopplin, Amde S. Shifera, Eric B. Suhler & Phoebe Lin. (2015) Biological Response Modifiers in the Treatment of Noninfectious Uveitis. International Ophthalmology Clinics 55:2, pages 19-36.
Crossref
Crossref
Marina Mesquida, Blanca Molins, Victor Llorenç, Maite Sainz de la Maza & Alfredo Adán. (2014) Long-Term Effects of Tocilizumab Therapy for Refractory Uveitis-Related Macular Edema. Ophthalmology 121:12, pages 2380-2386.
Crossref
Crossref
Emily H. Shao, Victor Menezo & Simon R.J. Taylor. (2014) Birdshot chorioretinopathy. Current Opinion in Ophthalmology 25:6, pages 488-494.
Crossref
Crossref
M Mesquida, A Leszczynska, V Llorenç & A Adán. (2014) Interleukin-6 blockade in ocular inflammatory diseases. Clinical and Experimental Immunology 176:3, pages 301-309.
Crossref
Crossref
Tania FidelixVirginia Fernandes Moça Trevisani. (2014) Imunobiológicos no tratamento das esclerites: revisão sistemática. Revista Paulista de Reumatologia:2014 jan-mar;13(1), pages 30-38.
Crossref
Crossref
Simone AppenzellerRoberto Marini. (2014) Uveíte na artrite idiopática juvenil. Revista Paulista de Reumatologia:2014 jan-mar;13(1), pages 17-20.
Crossref
Crossref
Un Chul Park, Tae Wan Kim & Hyeong Gon Yu. (2014) Immunopathogenesis of Ocular Behçet’s Disease. Journal of Immunology Research 2014, pages 1-13.
Crossref
Crossref
Phoebe Lin, Eric B. Suhler & James T. Rosenbaum. (2014) The Future of Uveitis Treatment. Ophthalmology 121:1, pages 365-376.
Crossref
Crossref
M. Papo, B. Bodaghi, B. Wechsler, A. Darugar, A. Muselier, P. Bielefeld, H. Vallet, T. Papo, P. Cacoub & D. Saadoun. (2013) Efficacité et tolérance du tocilizumab dans les uvéites inflammatoires non infectieuses sévères et réfractaires : une étude rétrospective sur 8 cas. La Revue de Médecine Interne 34, pages A26-A27.
Crossref
Crossref
Andreas Reiff, Sibel Kadayifcilar & Seza Özen. (2013) Rheumatic Inflammatory Eye Diseases of Childhood. Rheumatic Disease Clinics of North America 39:4, pages 801-832.
Crossref
Crossref
Alfredo Adán, Marina Mesquida, Victor Llorenç, Gerard Espinosa, Blanca Molins, Maria V. Hernández & Laura Pelegrín. (2013) Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology 251:11, pages 2627-2632.
Crossref
Crossref
Preema J. Mehta, Janet L. Alexander & H. Nida Sen. (2013) Pediatric uveitis. Current Opinion in Ophthalmology 24:5, pages 453-462.
Crossref
Crossref
Alfredo Adán, Victor Llorenç, Marina Mesquida & Laura Pelegrín. (2012) Tocilizumab treatment for recalcitrant uveitic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology 251:9, pages 2249-2250.
Crossref
Crossref
D. Saadoun, B. Bodaghi, B. Bienvenu, B. Wechsler, D. Sene, S. Trad, S. Abad, P. Cacoub, L. Kodjikian & P. Sève. (2013) Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies. Autoimmunity Reviews 12:7, pages 774-783.
Crossref
Crossref
Maria Pia Paroli, Alessandro Abbouda, Irene Abicca, Alfredo Sapìa & Marino Paroli. (2013) Biological agents in the treatment of uveitis. Advances in Bioscience and Biotechnology 04:08, pages 64-72.
Crossref
Crossref
Toshio Tanaka, Atsushi OgataMasashi Narazaki. (2013) Tocilizumab: An Updated Review of Its Use in the Treatment of Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases. Clinical Medicine Insights: Therapeutics 5, pages CMT.S9282.
Crossref
Crossref
Masaru Takeuchi. (2013) A systematic review of biologics for the treatment of noninfectious uveitis. Immunotherapy 5:1, pages 91-102.
Crossref
Crossref
Sanjay R. Kedhar. (2013) Research in Uveitis and Ocular Inflammation, 2011 to 2012. Asia-Pacific Journal of Ophthalmology 2:3, pages 187-198.
Crossref
Crossref
Daniel Wendling. (2012) Uveitis in Seronegative Arthritis. Current Rheumatology Reports 14:5, pages 402-408.
Crossref
Crossref
. (2012) Current World Literature. Current Opinion in Rheumatology 24:3, pages 342-349.
Crossref
Crossref
Lisa Kaly & Itzhak Rosner. (2012) Tocilizumab – A novel therapy for non-organ-specific autoimmune diseases. Best Practice & Research Clinical Rheumatology 26:1, pages 157-165.
Crossref
Crossref
John B. Christoforidis, Susie Chang, Angela Jiang, Jillian Wang & Colleen M. Cebulla. (2012) Systemic Treatment of Vitreous Inflammation. Mediators of Inflammation 2012, pages 1-10.
Crossref
Crossref
Inmaculada Calvo. 2012. Tratamiento de la uveítis con fármacos anti-TNF-alfa. Tratamiento de la uveítis con fármacos anti-TNF-alfa
67
75
.